去势抵抗型前列腺癌治疗的研究进展

路明 李(承德医学院附属医院，中国)
辉 徐(承德医学院附属医院，中国)

摘要

前列腺癌是中老年男性的常见疾病之一，中国前列腺癌的发病率、死亡率呈逐年升高趋势。早期前列腺癌患者可以通过根治性手术或放化疗进行治疗，然而多数前列腺癌患者就诊时已处于中晚期，甚至已发生远处转移，患者的生活质量受到极大影响。不过随着科技发展、诊疗水平日益提升，晚期前列腺癌的治疗方式快速革新，极大延长了患者的生存时间。但选择适合患者的治疗方案仍是临床难题，论文将对目前去势抵抗性前列腺癌的治疗手段进行综述。

关键词

前列腺癌；去势抵抗性前列腺癌；治疗药物

参考

Siegel R L, Miller K D, Wagle N S, et al. Cancer statistics, 2023[J]. Ca Cancer J Clin, 2023,73(1):17-48.

Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese medical journal, 2022, 135(5): 584-590.

Chen C D, Welsbie D S, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy[J]. Nature medicine, 2004, 10(1): 33-39.

Nishiyama T, Hashimoto Y, Takahashi K.The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer[J]. Clinical Cancer Research, 2004, 10(21): 7121-7126.

Tran C, Ouk S, Clegg N J, et al.Development of a second-generation antiandrogen for treatment of advanced prostate cancer[J]. Science, 2009, 324(5928): 787-790.

Scher H I, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. New England Journal of Medicine, 2012, 367(13): 1187-1197.

Tannock I F, De Wit R, Berry W R, et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. New England Journal of Medicine, 2004, 351(15): 1502-1512.

Berruti A, Pia A, Terzolo M. Abiraterone and increased survival in metastatic prostate cancer[J].New England Journal of Medicine ,2011 ,365: 766-766.

Fizazi K, Scher H I, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind,placebo-controlled phase 3 study[J].The lancet oncology, 2012, 13(10): 983-992.

Kantoff P W, Higano C S, Shore N D, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. New England Journal of Medicine, 2010, 363(5): 411-422.

Gulley J L, Borre M, Vogelzang N J, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer[J].Journal of Clinical Oncology,2019,37(13):1051.

Parsons J K,Pinto P A,Pavlovich C P,et al.A phase 2, double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillance[J]. European Urology Focus, 2023, 9(3): 447-454.

de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer[J]. New England Journal of Medicine, 2020, 382(22): 2091-2102.

Sartor O, De Bono J, Chi K N, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer[J]. New England Journal of Medicine, 2021, 385(12): 1091-1103.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i1.15602